Literature DB >> 69026

Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.

J A Beisler, M M Abbasi, J A Kelley, J S Driscoll.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 69026     DOI： 10.1021/jm00216a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  9 in total

1.  Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.

Authors:  H M Dhingra; W K Murphy; R J Winn; M N Raber; W K Hong
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

3.  2´-deoxy-5,6-dihydro-5-azacytidine - a less toxic alternative of 2´-deoxy-5-azacytidine: a comparative study of hypomethylating potential.

Authors:  Marika Matoušová; Ivan Votruba; Miroslav Otmar; Eva Tloušťová; Jana Günterová; Helena Mertlíková-Kaiserová
Journal:  Epigenetics       Date:  2011-06-01       Impact factor: 4.528

Review 4.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 5.  Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.

Authors:  Kunal Nepali; Jing-Ping Liou
Journal:  J Biomed Sci       Date:  2021-04-12       Impact factor: 8.410

6.  Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor.

Authors:  D S Zaharko; J M Covey; J A Kelley
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound.

Authors:  L Malspeis; H Cheng; A E Staubus
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 8.  Targeting DNA Methyltranferases in Urological Tumors.

Authors:  Ângela Marques-Magalhães; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Front Pharmacol       Date:  2018-04-13       Impact factor: 5.810

9.  2'-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2'-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile sites.

Authors:  Katarzyna Lamparska; Jarrod Clark; Gail Babilonia; Victoria Bedell; Wesley Yip; Steven S Smith
Journal:  Nucleic Acids Res       Date:  2012-07-31       Impact factor: 16.971
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.